(22 May 2024)
FOR CLEAN VERSION SEE STORY NUMBER: 4495950
++MUSIC CLEARED FOR EDITORIAL USE++
ASSOCIATED PRESS
Chattanooga, Tennessee – 21 May 2024
1. STILL Israel McKenzie stands for a portrait
2. SOUNDBITE (English) Israel McKenzie, 18 years old:
++VIDEO CALL++
++COVERED++
“Since I started taking Wegovy I’ve lost 110 pounds.”
3. SOUNDBITE (English) Israel McKenzie, 18 years old:
++VIDEO CALL++
++PARTIALLY COVERED++
“When it all started, I was 17 years old and I was struggling with my weight for a while. The first time I went to Dr. Jack’s was kind of life-changing. And when I got on Wegovy, I could — in the first few weeks I could see a difference.”
4. STILL Israel McKenzie stands for a portrait
ASSOCIATED PRESS
Temecula, California – 30 April 2024
5. STILL Wegovy injectable pens
ASSOCIATED PRESS
Cincinnati – 20 May 2024
6. SOUNDBITE (English): Dr. Joyce Lee, University of Michigan pediatrician:
++VIDEO CALL++
++PARTIALLY COVERED++
“Little has been known about the use of GLP-1 receptor agonist medications like Wegovy or Ozempic in younger patients. What we found was that there was a 594% increase in the GLP-1RA medication dispensing between 2020 and 2023 among adolescents and young adults in the US.”
ASSOCIATED PRESS
Temecula, California – 30 April 2024
7. STILL Stack of Wegovy boxes
ASSOCIATED PRESS
Hillerod, Denmark – 26 September 2023
8. Various of diabetes drug Ozempic going through automated packaging line at Novo Nordisk production facility
ASSOCIATED PRESS
Cincinnati – 20 May 2024
9. SOUNDBITE (English): Dr. Joyce Lee, University of Michigan pediatrician:
++VIDEO CALL++
++PARTIALLY COVERED++
“The trials that led to the approval of the medication, particularly in the adolescents — the kids were followed for a year. But I think we still have to understand what the real world use and impact is on long-term weight trajectories.”
ASSOCIATED PRESS
Hillerod, Denmark – 26 September 2023
10. Various of diabetes drug Ozempic at Novo Nordisk production facility
ASSOCIATED PRESS
Chattanooga, Tennessee – 21 May 2024
11. SOUNDBITE (English) Israel McKenzie, 18 years old:
++VIDEO CALL++
++PARTIALLY COVERED++
“I feel like if I hadn’t started Wegovy, it would have — the weight issue would have continued and increased and increased. Because I was pre-diabetic before I started it, and it was an actual physical health risk. And now I’m not. And my health has overall improved dramatically.”
12. STILL Israel McKenzie stands for a portrait
STORYLINE:
At 17, Israel McKenzie was so burdened by obesity that he stopped going to high school in person and dreaded meeting people at his part-time restaurant job.
“I was struggling with my weight for a while,” says McKenzie, whose weight had climbed to 335 pounds on his 6-foot-1 frame, despite repeated efforts to diet and exercise.
But last year, the weight-loss drug Wegovy helped him shed 110 pounds in nine months, making the Tennessee teen part of a surge of adolescents and young adults using diabetes and obesity medications known as GLP-1 receptor agonists, new research shows.
Even as millions of older adults clamor for drugs such as Ozempic and Wegovy, monthly use of the medications soared in people aged 12 to 25. That’s according to a new analysis of dispensing records from nearly 94% of U.S. retail pharmacies from 2020 to 2023.
“It really gives us a full national picture of the extent to which prescribing and dispensing has increased in the adolescent and young adult population,” she said.
“My health has overall improved dramatically,” he said.
___
Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Twitter: https://twitter.com/AP_Archive
Facebook: https://www.facebook.com/APArchives
Instagram: https://www.instagram.com/APNews/
You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/c6a0e1c987b049cc9b7ffc8ffafe3b12
Author: AP Archive
Go to Source
News post in December 1, 2024, 3:04 pm.
Visit Our Sponsor’s:
News Post In – News
